Evaluation of a Panel of Recombinant Respiratory Syncytial Virus (RSV) Strains to Antimicrobial Peptide Inactivation

Karina Latsko Butler University, Caitlin Haas Butler University, Nathan Junod Butler University, Katelyn Castiglia Butler University
Faculty Sponsor(s): Christopher Stobart Butler University
Antimicrobial peptides are small proteins found in a large variety of life forms that are able to kill microbial pathogens either directly or indirectly and aid in the body’s natural immune response. Respiratory Syncytial Virus, or RSV, is a upper and lower respiratory pathogen that can be detrimental to both young infants and the elderly. It currently has no viable vaccine due to its poor ability to elicit an immune response in bodily cells, its physical and genetic instability, and a long legacy of vaccine-enhanced disease. Treatment options after RSV contraction are limited, however, recent studies have shown that the antimicrobial peptides cathelicidin and defensins have been able to inactivate the A2 laboratory strain of RSV. However, there are multiple strains of RSV each with their own unique structure and replication patterns that had not been covered by previous studies. In this study, we tested the efficacy of multiple different categories of antimicrobial peptides against recombinant RSV strains that express the attachment and fusion proteins of laboratory and clinical strains of RSV. We used inactivation and replication assays to evaluate the efficiency of inactivation of the recombinant RSV strains against several antimicrobial peptides. This studies demonstrate the efficacy of antimicrobial peptides in limiting RSV infection and could have further implications in options for treatment of active RSV infections.
Oral Presentation

When & Where

09:30 AM
Gallahue Hall 106